Trading
Data
Solutions
Insights
About
Sionna Therapeutics is a life science company that aims to develop treatments for cystic fibrosis. The company works to research drug treatments for the disorder striving to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is essential for the regulation of salt and water balance in the body. Sionna Therapeutics was founded by Greg Hurlbut and Mark Munson in 2019 and is headquartered in Boston, MA.
Sionna Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Sionna Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Sionna Therapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 3/6/2024 | Series C | $181.86MM raised | $XXX.XX | $XXX.XX |
| 4/19/2022 | Series B | $111MM raised | $XXX.XX | $XXX.XX |
| 6/30/2021 | Series A | $25.26MM raised | $XXX.XX | $XXX.XX |
| 6/30/2020 | Series Seed | $13.2MM raised | $XXX.XX | $XXX.XX |
